Penka S. Petrova

1.2k citations

22 papers · 546 indexed · h-index 9

Immunology
Cellular and Molecular Neuroscience top 10%
Cell Biology top 10%
Molecular Biology
Oncology

Co-authors: Mordechai Anafi Jonathan Pevsner Yves Durocher John Kelly Jeremy C. Smith John W. Commissiong Amy Peaire Viji Shridhar
Topics: Phagocytosis and Immune Regulation (16 papers)Immune cells in cancer (7 papers)Immunotherapy and Immune Responses (5 papers)
Cited by: Developmental Neuroscience Immunology Cellular and Molecular Neuroscience
Journals: Journal of Clinical Oncology Blood PLoS ONE
Partner nations: United States Canada United Kingdom

In The Last Decade

Penka S. Petrova

22 papers receiving 535 citations

Peers

Countries citing papers authored by Penka S. Petrova

Since Specialization

Citations

This map shows the geographic impact of Penka S. Petrova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penka S. Petrova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penka S. Petrova more than expected).

Fields of papers citing papers by Penka S. Petrova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penka S. Petrova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penka S. Petrova. The network helps show where Penka S. Petrova may publish in the future.

Co-authorship network of co-authors of Penka S. Petrova

This figure shows the co-authorship network connecting the top 25 collaborators of Penka S. Petrova. A scholar is included among the top collaborators of Penka S. Petrova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Penka S. Petrova. Penka S. Petrova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study 2021 ·The Lancet Haematology ·Christiane Querfeld,John A. Thompson,Matthew H. Taylor,Jennifer DeSimone,Jasmine Zain,Andrei R. Shustov,(unknown),(unknown),Gloria H. Y. Lin,Penka S. Petrova,Robert A. Uger,(unknown),Yaping Shou,Oleg E. Akilov	56
2	CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study 2021 ·Blood ·Krish Patel,Jeffrey A. Zonder,(unknown),Michael B. Maris,Alexander M. Lesokhin,Gottfried von Keudell,Catherine Lai,(unknown),(unknown),Gloria H. Y. Lin,(unknown),Penka S. Petrova,(unknown),Ingmar Bruns,Swaminathan P. Iyer	20
3	Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study 2020 ·Blood ·Krish Patel,Radhakrishnan Ramchandren,Michael B. Maris,Alexander M. Lesokhin,(unknown),Bruce D. Cheson,Jeff Zonder,Erlene Seymour,(unknown),Gloria H. Y. Lin,(unknown),Penka S. Petrova,(unknown),Yaping Shou,Swaminathan P. Iyer	14
4	Abstract 2720: The CD47-blocking innate immune checkpoint inhibitor, TTI-621, triggers CD47-mediated tumor cell apoptosis 2018 ·Cancer Research ·(unknown),Natasja Nielsen Viller,Xinli Pang,Penka S. Petrova,Robert A. Uger,(unknown),Emma Linderoth	1
5	Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial 2018 ·Blood ·Christiane Querfeld,John A. Thompson,Matthew H. Taylor,Raju Pillai,Lisa D. Johnson,(unknown),Penka S. Petrova,(unknown),Robert A. Uger,Yaping Shou,Oleg E. Akilov	8
6	Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial 2018 ·European Journal of Cancer ·Christiane Querfeld,John A. Thompson,Matthew H. Taylor,Raju Pillai,Lisa D. Johnson,(unknown),Penka S. Petrova,(unknown),(unknown),(unknown),Eric L. Sievers,Oleg E. Akilov	7
7	Investigating the Efficacy of Anti-CD200 Immunotherapy in MRD Low and Risk B Cell Precursor ALL 2017 ·Blood ·Paraskevi Diamanti,(unknown),Charlotte V. Cox,Penka S. Petrova,Robert A. Uger,Allison Blair	1
8	A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal 2017 ·Blood ·Christiane Querfeld,John A. Thompson,Matthew H. Taylor,Raju Pillai,Lisa D. Johnson,(unknown),Penka S. Petrova,Robert A. Uger,(unknown),Eric L. Sievers,Oleg E. Akilov	15
9	TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets 2017 ·PLoS ONE ·Gloria H. Y. Lin,(unknown),Vivian Lee,Karen Dodge,(unknown),Mark Wong,Lisa D. Johnson,Emma Linderoth,Xinli Pang,(unknown),Penka S. Petrova,Robert A. Uger,Natasja Nielsen Viller	51
10	Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model 2017 ·Cancer Research ·Gloria H. Y. Lin,(unknown),(unknown),(unknown),(unknown),Hui Chen,Mark Wong,Natasja Nielsen Viller,Emma Linderoth,Lisa D. Johnson,Xinli Pang,(unknown),Penka S. Petrova,Robert A. Uger	1
11	A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. 2017 ·Journal of Clinical Oncology ·John A. Thompson,Oleg E. Akilov,Christiane Querfeld,Matthew H. Taylor,Lisa D. Johnson,(unknown),Penka S. Petrova,Robert A. Uger,(unknown),Eric L. Sievers	4
12	Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial. 2017 ·Journal of Clinical Oncology ·Lisa D. Johnson,Raju Pillai,Rebecca L. King,Stephen M. Ansell,Robert W. Chen,Ian W. Flinn,Michael B. Maris,(unknown),Eric L. Sievers,Penka S. Petrova,Robert A. Uger	3
13	Abstract 2345: SIRPαFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages 2016 ·Cancer Research ·Gloria H. Y. Lin,(unknown),Vivian Lee,Karen Dodge,(unknown),Mark Wong,Lisa D. Johnson,Xinli Pang,Penka S. Petrova,Robert A. Uger,Natasja Nielsen Viller	1
14	Abstract B028: Blockade of the CD47 “Do not eat” signal by TTI-621 (SIRPαFc) leads to enhanced antitumor CD8+ T cell responses in vitro 2016 ·Cancer Immunology Research ·Natasja Nielsen Viller,(unknown),Emma Linderoth,Lisa D. Johnson,Stéphane Viau,Gloria H. Y. Lin,Mark Wong,Xinli Pang,Penka S. Petrova,Robert A. Uger	1
15	Investigating the Effects of Anti-CD200 Therapy for Childhood ALL 2016 ·Blood ·Paraskevi Diamanti,Charlotte V. Cox,(unknown),Penka S. Petrova,Robert A. Uger,Allison Blair	2
16	Abstract 4271: Lack of CD47 membrane mobility contributes to the poor erythrocyte binding of SIRPαFc, a novel CD47-blocking cancer immunotherapeutic 2015 ·Cancer Research ·Penka S. Petrova,Karen Dodge,Tanya Prasolava,(unknown),Xinli Pang,Robert A. Uger	1
17	Abstract 5011: Cancer immunotherapy targeting CD47: Wild type SIRPαFc is the ideal CD47-blocking agent to minimize unwanted erythrocyte binding 2014 ·Cancer Research ·Robert A. Uger,Karen Dodge,Xinli Pang,Penka S. Petrova	2
18	Blockade Of CD47 Using SIRPαFc: Role Of The Fc Region In Anti-Leukemic Activity and Tolerability 2013 ·Blood ·Robert A. Uger,Xinli Pang,Mark Wong,(unknown),Karen Dodge,Stéphane Viau,(unknown),(unknown),(unknown),Liqing Jin,(unknown),Jenny Ho,(unknown),Jayne S. Danska,Jean Wang,Penka S. Petrova	3
19	Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases 2004 ·Progress in brain research ·Penka S. Petrova,(unknown),Jonathan Pevsner,(unknown),Mordechai Anafi,(unknown),Amy Peaire,Viji Shridhar,Jeremy C. Smith,John Kelly,Yves Durocher,John W. Commissiong	30
20	MANF: A New Mesencephalic, Astrocyte-Derived Neurotrophic Factor with Selectivity for Dopaminergic Neurons 2003 ·Journal of Molecular Neuroscience ·Penka S. Petrova,(unknown),Jonathan Pevsner,(unknown),Mordechai Anafi,(unknown),Amy Peaire,Viji Shridhar,Jeremy C. Smith,John Kelly,Yves Durocher,John W. Commissiong	290

About Penka S. Petrova

Penka S. Petrova is a scholar working on Immunology, Developmental Neuroscience and Neurology, having authored 22 papers that have together received 546 indexed citations. Recurring topics across this work include Phagocytosis and Immune Regulation (16 papers), Immune cells in cancer (7 papers) and Immunotherapy and Immune Responses (5 papers). The work is most often cited by research in Developmental Neuroscience (46 citations), Immunology (213 citations) and Cellular and Molecular Neuroscience (163 citations). Penka S. Petrova has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Mordechai Anafi, Jonathan Pevsner, Yves Durocher, John Kelly, Jeremy C. Smith, John W. Commissiong, Amy Peaire, Viji Shridhar, Robert A. Uger and Gloria H. Y. Lin. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact